|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The synthetic PTHrP(1-34) analog abaloparatide (ABL) is a newly approved drug for osteoporosis therapy.
|
30654932 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abaloparatide, a novel analog of parathyroid hormone-related protein (PTHrP 1-34) became, in 2017, the second osteoanabolic therapy for the treatment of osteoporosis.
|
31793033 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two endogenous peptide ligands, parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP), activate the receptor, and their analogs teriparatide and abaloparatide are used in the clinic to increase bone formation as an effective yet costly treatment for osteoporosis.
|
30455434 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
N-terminal PTH (teriparatide) and now a modified N-terminal PTHrP (abaloparatide) are US Food and Drug Administration (FDA)-approved therapies for osteoporosis.
|
28914969 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone and parathyroid hormone-related protein analogs, whether as monotherapy, in combination with antiresorptive agents or in sequence with antiresorptive agents, will likely play an expanding role in osteoporosis management.
|
28303448 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most promising new drugs in the treatment of osteoporosis include the antibody that neutralizes RANKL (denosumab, DMAb), monoclonal antibodies against sclerostin and parathyroid hormone-related protein analogue.
|
28707576 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abaloparatide, a synthetic analog of parathyroid hormone-related protein, has received regulatory approval for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
|
28756709 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone (PTH, 84 residues) and PTH-related protein (PTHrP, 141 residues) are natural agonists of PTHR1, and an N-terminal fragment of PTH, PTH(1-34), is used clinically to treat osteoporosis.
|
29064243 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anabolic agents, mainly PTH, are usually combined with other anti-resorptive drugs, and PTHrP might be a promising pure anabolic agent for osteoporosis.
|
28521692 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
|
28159062 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies mainly in osteoporosis rodent models and limited data in postmenopausal women suggest that N-terminal PTHrP peptides might be considered a promising bone anabolic therapy.
|
23500550 |
2013 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Now, research into the basic biology of PTHrP has suggested previously unrecognized connections to a variety of disease states such as osteoporosis, osteoarthritis, and breast cancer and has highlighted how PTHrP itself might be used in therapy for osteoporosis and diabetes.
|
22745236 |
2012 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice with osteoblast-specific deletion of parathyroid hormone-related protein (PTHrP) exhibit impaired recruitment and increased apoptosis of osteogenic cells resulting in decreased bone formation and premature osteoporosis.
|
18426836 |
2008 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this mini-review, the theoretical basis for the exploration and development of PTHrP(1-36) as a potential therapeutic agent for osteoporosis is considered.
|
8894135 |
1996 |